Highlights Soleno Therapeutics, Inc.

Equities

SLNO

US8342033094

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
44.27 ^USD	-5.83%		+1.77%	+9.99%

May. 13	Oppenheimer Adjusts Price Target on Soleno Therapeutics to $59 From $65, Maintains Outperform Rating	MT
May. 10	Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Soleno Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Soleno Therapeutics Prices $138 Million Stock Offering	May. 03	MT
Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to Natural History of Prader-Willi Syndrome	Apr. 30	CI
Soleno Therapeutics' Shares Jump After FDA Grants Breakthrough Designation for Prader-Willi Syndrome Treatment	Apr. 29	MT
Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome	Apr. 29	CI
Soleno Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Soleno Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
Soleno Therapeutics Files Mixed Shelf	Jan. 03	MT
Soleno Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open Label Study of DCCR in Prader-Willi Syndrome	Nov. 06	CI
Soleno Therapeutics, Inc. Announces Positive Statistically Significant Top-Line Results from Randomized Withdrawal Period of Study C602 of Dccr for Prader-Willi Syndrome	23-09-26	CI
Soleno Therapeutics Appoints Matthew Pauls to Board of Directors	23-08-16	CI
Soleno Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Soleno Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome	23-05-03	CI
Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome	23-01-26	CI
Note 2. Going Concern and Management's Plans	22-11-09	AQ
Soleno Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Soleno Therapeutics, Inc. Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome	22-10-03	CI
Note 2. Going Concern and Management's Plans	22-08-10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Soleno Therapeutics, Inc.

Equities

SLNO

US8342033094

Highlights

Filters